Mar 06, 2020
FDA Approves New Treatment for Adults with Cushing's Disease
Feb 20, 2020
Recordati Rare Diseases, Inc. Announces Transfer of U.S. Marketing Rights to SIGNIFOR® (pasireotide) Injection and SIGNIFOR LAR® (pasireotide) for Injectable Suspension
Oct 22, 2019
BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference
Aug 30, 2019
Mitotane Market is Expected to Grow With a CAGR of ~ 5% in the Forecast Period - PMR
Mar 25, 2019
Spruce Biosciences Achieves Proof of Concept in Phase 2 Study of Tildacerfont in Congenital Adrenal Hyperplasia
Mar 12, 2019
Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia
Mar 08, 2019
Spruce Biosciences Announces Presentation of Positive Topline Data from Phase 2 Study of Tildacerfont (SPR001) in Congenital Adrenal Hyperplasia at the 2019 Annual Meeting of the Endocrine Society (ENDO)
Feb 20, 2019
Sosei Heptares Starts New Clinical Development Program
Nov 05, 2018
Exclusive Forecast Study Observes Cushings Syndrome and Acromegaly Treatment Market to Incur Value Growth at 9.3% CAGR During 2018 - 2026 Persistence Market Research
Sep 19, 2018
Cushing's Syndrome Epiomic Epidemiology Forecast 2018-2028 by Gender and 5-Year Age Cohort
Sep 17, 2018
Congenital Adrenal Hyperplasia Epiomic Epidemiology Forecasts 2018-2028
Jul 30, 2018
FDA approves first treatment for rare adrenal tumors
Jan 05, 2018
Spruce Biosciences Receives EMA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia
Oct 12, 2017
Spruce Biosciences Provides Corporate Update on Series A Venture Financing, Leadership Team and Lead Clinical Program